옵션 체인은 다양한 행사가격과 만기일에 대한 Cellectar Biosciences의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Cellectar Biosciences에 대한 시장 심리를 평가합니다..

Cellectar Biosciences (NASDAQ:CLRB) 주식, 옵션 체인

Cellectar Biosciences

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences Inc

WIIM

CLRB

Cellectar Biosciences shares are trading lower. The company announced it entered into definitive agreements to raise $2.5 million from the sale of shares.

Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million&nbsp;from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
Ladenburg Thalmann &amp; Co. Inc. is acting as the exclusive placement agent for the offering.
The agreements provide for the immediate exercise of certain outstanding warrants to purchase an aggregate of 8,301,322 shares of common stock, issued by the company on June 5, 2020, October 25, 2022 and July 21, 2024 (the "Existing Warrants"), at a reduced exercise price of $0.3041 per share. The shares of common stock issuable upon exercise of the Existing Warrants are all registered, or their resale is registered, pursuant to effective registration statements. The company did not issue any replacement warrants. The gross proceeds to the company from the exercise of the Existing Warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. The company intends to use the net proceeds for general corporate purposes, including working capital and operating expenses.

News

Cellectar Biosciences Enters Into Definitive Agreements To Raise $2.5M From Sale Of Shares Priced At-Market For Nasdaq Purposes

<h3>Gainers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 89.2% to $24.05 during Wednesday's after-market session. The market value of their outstanding shares is at $642.4 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares moved upwards by 27.84% to $0.73. The market value of their outstanding shares is at $5.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 12.55% to $4.8. The market value of their outstanding shares is at $73.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock increased by 10.43% to $0.51. The market value of their outstanding shares is at $23.4 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 7.09% to $0.6. The company's market cap stands at $15.3 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock rose 5.56% to $0.84. The market value of their outstanding shares is at $22.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock fell 17.4% to $1.95 during Wednesday's after-market session. The company's market cap stands at $63.7 million. </li>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) stock decreased by 15.86% to $9.37. The market value of their outstanding shares is at $511.2 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares fell 12.31% to $0.28. The company's market cap stands at $10.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares decreased by 7.82% to $0.48. The market value of their outstanding shares is at $8.0 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 6.48% to $1.59. The company's market cap stands at $27.8 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 6.33% to $10.73. The market value of their outstanding shares is at $1.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCAX

BOLT

CBUS

FEMY

IMNN

KAPA

LIMN

MESO

MHUA

SILO

12 Health Care Stocks Moving In Wednesday's After-Market Session

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.
The Dow traded up 0.09% to 42,558.84 while the NASDAQ rose 0.31% to 19,459.23. The S&amp;P 500 also rose, gaining, 0.19% to 5,981.93.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 1.1% on Wednesday.
In trading on Wednesday, energy stocks fell by 1.7%.
Top Headline
The ISM services PMI dipped to 49.9 in May versus 51.6 in the previous month and also missing market estimates of 52.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) shares shot up 33% to $9.08 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Shares of K Wave Media Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) got a boost, surging 115% to $4.1303 after the company announced it signed a $500 million securities purchase agreement to advance a bitcoin-focused treasury strategy.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares were also up, gaining 61% to $0.4466 after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares dropped 17% to $15.78 following first-quarter results.</li>
<li>Shares of AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) were down 10% to $21.19 after the company announced Rosnilimab data from its six-month Phase 2b trial for rheumatoid arthritis (RA).</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) was down, falling 8% to $89.00 after the company posted first-quarter results.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $62.64 while gold traded up 0.7% at $3,398.90.
Silver traded down 0.2% to $34.56 on Wednesday, while copper rose 0.8% to $4.8710.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.55%, while Spain's IBEX 35 Index fell 0.14%. London's FTSE 100 rose 0.20%, Germany's DAX 40 gained 0.76% and France's CAC 40 rose 0.64% during the session.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei gaining 0.80%, Hong Kong's Hang Seng Index jumping 0.60%, China's Shanghai Composite gaining 0.42% and India's BSE Sensex gaining 0.32%.
Economics
<ul class="wp-block-list">
<li>The EIA said crude oil inventories in the U.S. declined by 4.304 million barrels in the week ended May 30, compared to market estimates of a 0.9 million barrel fall.</li>
<li>The ISM services PMI dipped to 49.9 in May versus 51.6 in the previous month and also missing market estimates of 52.</li>
<li>The S&amp;P Global composite PMI was revised higher to 53.0 in May compared to a preliminary reading of 52.1 and versus April's reading of 50.6.</li>
<li>U.S. private business added 37K workers to their payrolls during May versus a revised 60K gain in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45771113/this-apple-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday-2">This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ANAB

ASAN

DLTR

YEXT

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares increased by 84.2% to $6.89 during Wednesday's regular session. The company's market cap stands at $7.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock increased by 61.52% to $0.45. The market value of their outstanding shares is at $20.6 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares increased by 44.59% to $1.33. The company's market cap stands at $17.5 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 39.58% to $2.68. The market value of their outstanding shares is at $38.4 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares rose 35.87% to $0.4. The company's market cap stands at $16.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) shares rose 30.0% to $5.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock declined by 28.1% to $4.85 during Wednesday's regular session. The company's market cap stands at $3.5 million. </li>
<li>Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares decreased by 23.22% to $4.61. The company's market cap stands at $999.4 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 22.75% to $0.05. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock fell 21.57% to $0.66. The company's market cap stands at $9.3 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares fell 18.27% to $2.64. The market value of their outstanding shares is at $2.1 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares declined by 17.92% to $22.64. The market value of their outstanding shares is at $30.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCCP

HOTH

LYRA

MBRX

MODV

NCNA

NEOG

RLYB

RSLS

STSS

12 Health Care Stocks Moving In Wednesday's Intraday Session

Cellectar Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock is trading higher on Wednesday.
As per data from Benzinga Pro, session volume stands at 361.96 million versus an <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">average volume of 968.03k</a>.
What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company&#8217;s iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">macroglobulinemia (r/r WM)</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/12/42442003/cellectar-biosciences-stock-plunges-as-cancer-focused-cancer-firm-pursues-strategic-options" target="_blank" rel="noreferrer noopener">Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options</a>
Why It Matters: WM is the dominant subtype of lymphoplasmacytic lymphoma.
Data from the Phase 2 CLOVER WaM study, including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2%, which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented during the 66th Annual American Society of Hematology Conference in December 2024.
As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45768008/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-mac" rel="noreferrer noopener">and Orphan Drug Designation</a>.
The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I&nbsp;131 for r/r WM and PRIME Designation for WM.
What&#8217;s Next: Separately, the company has provided the EMA with a data package that includes extensive supportive preclinical, regulatory, and manufacturing data and safety and efficacy data from the CLOVER WaM Phase 2b clinical trial.
The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval.
In late July 2025, the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application.
Price Action: CLRB stock is trading higher by 57.9% to $0.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/06/45770622/sprinklr-rises-on-solid-earnings-raised-outlook-and-new-150-million-buyback-plan" target="_blank" rel="noreferrer noopener">Sprinklr Rises On Solid Earnings, Raised Outlook, And New $150 Million Buyback Plan</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Health Care

General

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.17% to 42,591.06 while the NASDAQ rose 0.34% to 19,465.31. The S&amp;P 500 also rose, gaining, 0.27% to 5,986.07.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 1% on Wednesday.
In trading on Wednesday, utilities stocks fell by 0.6%.
Top Headline
Shares of Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) fell more than 10% on Wednesday after its first-quarter 2025 earnings report.
Net sales increased 11.3% to $4.6 billion, beating the consensus of $4.53 billion and the management guidance of $4.5 billion—$4.6 billion.
Same-store net sales increased 5.4%, driven by a 2.5% increase in traffic and a 2.8% increase in average ticket, beating the management guidance growth of 3% – 5%. Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21, better than management expectation of $1.10 – $1.25.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares shot up 191% to $15.69.</li>
<li>Shares of K Wave Media Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) got a boost, surging 124% to $4.3046 after the company announced it signed a $500 million securities purchase agreement to advance a bitcoin-focused treasury strategy.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares were also up, gaining 100% to $0.5581 after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>PTL Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) shares dropped 41% to $0.4300.</li>
<li>Shares of Raytech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) were down 27% to $1.1906.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) was down, falling 23% to $5.19. ReShape Lifesciences recently announced its Quality Management System and entire commercial portfolio of medical devices sold in Europe and in the UK have been certified under the European Union Medical Device Regulation 2017/745 and UK Conformity Assessment.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $63.26 while gold traded up 0.8% at $3,402.30.
Silver traded up 0.1% to $34.665 on Wednesday, while copper rose 1.1% to $4.8865.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.5%, while Spain's IBEX 35 Index fell 0.2%. London's FTSE 100 rose 0.3%, Germany's DAX 40 gained 0.6% and France's CAC 40 rose 0.7% during the session.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei gaining 0.80%, Hong Kong's Hang Seng Index jumping 0.60%, China's Shanghai Composite gaining 0.42% and India's BSE Sensex gaining 0.32%.
Economics
<ul class="wp-block-list">
<li>The EIA said crude oil inventories in the U.S. declined by 4.304 million barrels in the week ended May 30, compared to market estimates of a 0.9 million barrel fall.</li>
<li>The ISM services PMI dipped to 49.9 in May versus 51.6 in the previous month and also missing market estimates of 52.</li>
<li>The S&amp;P Global composite PMI was revised higher to 53.0 in May compared to a preliminary reading of 52.1 and versus April's reading of 50.6.</li>
<li>U.S. private business added 37K workers to their payrolls during May versus a revised 60K gain in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45771113/this-apple-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday-2">This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday</a> </li>
</ul>
Photo via Shutterstock

MULN

PTLE

US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings

Cellectar Biosciences shares are trading higher after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.

Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR)
Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July
FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
WM is the dominant subtype of lymphoplasmacytic lymphoma and remains incurable with available therapies according to the International Waldenstrom's Macroglobulinemia Foundation. Approved WM treatment options are limited, underscoring the need for new therapies with novel mechanisms of action.

Cellectar's Iopofosine I-131 Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory Waldenstrom Macroglobulinemia Based On CLOVER WaM Phase 2 Study Showing 83.6% Response Rate; EMA Guidance On Conditional Approval Pathway Expected By Late July

Maxim Group analyst Jason McCarthy downgrades Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Maxim Group Downgrades Cellectar Biosciences to Hold

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 81.08 percent increase over losses of $(0.74) per share from the same period last year.

Earnings Beats

Cellectar Biosciences Q1 EPS $(0.14) Beats $(0.16) Estimate, Cash $13.9M

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Cellectar Biosciences will report an earnings per share (EPS) of $-0.16.
Anticipation surrounds Cellectar Biosciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.34, which was followed by a 5.34% increase in the share price the next day.
Here's a look at Cellectar Biosciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.35</td>
<td>-0.37</td>
<td>-1</td>
<td>-0.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.40</td>
<td>-0.18</td>
<td>-0.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-9.0%</td>
<td>0.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747077057_0.png" alt="eps graph" />
<h3>Market Performance of Cellectar Biosciences's Stock</h3>
Shares of Cellectar Biosciences were trading at $0.2474 as of May 09. Over the last 52-week period, shares are down 91.9%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CLRB/earnings">To track all earnings releases for Cellectar Biosciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Cellectar Biosciences's Quarterly Earnings

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 132.5% to $7.83 during Wednesday's regular session. The company's market cap stands at $519.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 71.13% to $54.08. The company's market cap stands at $703.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares increased by 62.72% to $2.62. The company's market cap stands at $12.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares moved upwards by 30.18% to $6.9. The market value of their outstanding shares is at $334.8 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 24.26% to $7.06. The company's market cap stands at $78.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 20.73% to $1.31. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock declined by 38.7% to $71.69 during Wednesday's regular session. The company's market cap stands at $2.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock decreased by 23.59% to $2.83. The company's market cap stands at $2.3 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock declined by 21.78% to $7.76. The market value of their outstanding shares is at $25.1 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 21.53% to $1.75. The market value of their outstanding shares is at $52.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $103.4 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares fell 15.54% to $0.25. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

BCLI

COEP

IMUX

NAOV

NTRB

RGLS

ZYXI

CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company announced a plan to explore strategic alternatives.

Cellectar Biosciences shares are trading higher after the company announced a plan to explore strategic alternatives.

Cellectar Biosciences To Explore Strategic Alternatives

Guidance

Cellectar Biosciences Says Its Cash Balance Of $23.3M As Of December 31, 2024, Is Adequate To Fund Its Basic Budgeted Operations Into The Fourth Quarter Of 2025

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.59) by 11.95 percent. This is a 60 percent increase over losses of $(3.50) per share from the same period last year.

Cellectar Biosciences FY 2024 GAAP EPS $(1.40) Beats $(1.59) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $11.76 million. 
• Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $28.55 million. 
• Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $15.80 million. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is expected to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $54.11 million. 
• Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) is expected to report earnings for its fourth quarter. 
• US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $4.54 million. 
• Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $37.36 million. 
• G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $807.11 million. 
• Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report earnings for its fourth quarter. 
• Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is projected to report quarterly loss at $0.16 per share on revenue of $13.39 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $8.67 million. 
• D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $2.23 million. 
• Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $81.68 million. 
• Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $204.70 million. 
• CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $27.99 million. 
• Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $50.53 million. 
• Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $10.26 billion. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $147.53 million. 
• Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is estimated to report earnings for its fourth quarter. 
• Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $499.61 million. 
• Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is projected to report quarterly loss at $0.49 per share on revenue of $142.21 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $25.15 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report earnings for its fourth quarter. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is expected to report earnings for its fourth quarter. 
• Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $76.67 million. 
• Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is likely to report quarterly loss at $0.47 per share on revenue of $2.67 million. 
• Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter. 
• Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is estimated to report earnings for its fourth quarter. 
• Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly loss at $0.07 per share on revenue of $47.75 million. 
• Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $252.86 million. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $451.76 million. 
• Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $42.80 million. 
<h3>Companies Reporting After The Bell</h3>
• Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $394.49 million. 
• DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $761.31 million. 
• Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.08 per share on revenue of $130.60 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is likely to report quarterly earnings at $1.82 per share on revenue of $1.63 billion. 
• Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is expected to report earnings for its third quarter. 
• Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is likely to report quarterly loss at $0.35 per share on revenue of $118.90 million. 
• Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.10 per share on revenue of $10.37 million. 
• Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) is projected to report quarterly loss at $0.21 per share on revenue of $9.09 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is expected to report earnings for its fourth quarter. 
• Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is estimated to report quarterly earnings at $0.77 per share on revenue of $253.99 million. 
• Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is expected to report earnings for its fourth quarter. 
• Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.63 per share on revenue of $3.08 million. 
• Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $161.36 million. 
• FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is expected to report quarterly loss at $0.04 per share on revenue of $29.02 million. 
• aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) is projected to report earnings for its fourth quarter. 
• Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $142.61 million. 
• PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $7.70 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $108.91 million. 
• Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is expected to report quarterly loss at $0.18 per share on revenue of $12 thousand. 
• Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $2.77 million. 
• WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $46.00 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $250.17 million. 
• Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $276.46 million. 
• OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $92.09 million. 
• Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $30.77 million. 
• HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is estimated to report earnings for its fourth quarter. 
• Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $102.27 million. 
• AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is expected to report earnings for its fourth quarter. 
• PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is likely to report quarterly loss at $0.11 per share on revenue of $14.30 million. 
• Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is projected to report quarterly loss at $1.11 per share on revenue of $23.52 million. 
• Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $22.29 million. 
• Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $81.42 million. 
• ZOMEDICA CORP COM (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $8.10 million. 
• GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is projected to report quarterly loss at $0.11 per share on revenue of $42.21 million. 
• Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $40.13 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $119.53 million. 
• EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $170.48 million. 
• Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $36.08 million. 
• AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $74.60 million. 
• Origin Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $9.08 million. 
• Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $12.30 million. 
• Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is likely to report quarterly loss at $0.39 per share on revenue of $232.91 million. 
• Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $348.33 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its first quarter. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is estimated to report quarterly earnings at $7.13 per share on revenue of $3.47 billion. 
• Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.33 million. 
• Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $5.00 million. 
• Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $28.95 million. 
• BuzzFeed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZFD#NASDAQ">BZFD</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Cellectar Biosciences

Cellectar Biosciences (CLRB) 옵션

Cellectar Biosciences (NASDAQ:CLRB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌